Exact Sciences Corporation (NASDAQ:EXAS) CFO Jeffrey Thomas Elliott sold 5,846 shares of the stock in a transaction on Monday, July 31st. The shares were sold at an average price of $39.41, for a total transaction of $230,390.86. Following the transaction, the chief financial officer now owns 19,861 shares in the company, valued at $782,722.01. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Exact Sciences Corporation (NASDAQ:EXAS) traded up 1.09% during mid-day trading on Friday, hitting $37.87. 1,039,106 shares of the company were exchanged. The stock’s 50 day moving average is $38.05 and its 200-day moving average is $29.56. The company’s market cap is $4.51 billion. Exact Sciences Corporation has a 12-month low of $13.05 and a 12-month high of $42.18.
Exact Sciences Corporation (NASDAQ:EXAS) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.10. The company had revenue of $57.65 million during the quarter, compared to analysts’ expectations of $47.73 million. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. Equities research analysts predict that Exact Sciences Corporation will post ($1.18) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Rincon Hill News and is owned by of Rincon Hill News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://rinconhillneighbors.org/2017/08/19/jeffrey-thomas-elliott-sells-5846-shares-of-exact-sciences-corporation-exas-stock-updated-updated.html.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Fortaleza Asset Management Inc. bought a new position in shares of Exact Sciences Corporation during the second quarter worth about $106,000. Krilogy Financial LLC boosted its position in Exact Sciences Corporation by 1,460.0% in the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after buying an additional 3,650 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in Exact Sciences Corporation by 17.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after buying an additional 600 shares in the last quarter. Financial Architects Inc boosted its position in Exact Sciences Corporation by 90.0% in the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock worth $152,000 after buying an additional 2,035 shares in the last quarter. Finally, Johnson Financial Group Inc. boosted its position in Exact Sciences Corporation by 25.9% in the second quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock worth $172,000 after buying an additional 1,000 shares in the last quarter. 85.44% of the stock is owned by institutional investors.
A number of analysts have weighed in on the stock. Zacks Investment Research cut shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Jefferies Group LLC set a $35.00 target price on shares of Exact Sciences Corporation and gave the stock a “buy” rating in a report on Thursday, June 1st. Vetr cut shares of Exact Sciences Corporation from a “strong-buy” rating to a “hold” rating and set a $35.91 target price on the stock. in a report on Wednesday, May 31st. Cowen and Company reissued an “outperform” rating and set a $45.00 target price on shares of Exact Sciences Corporation in a report on Wednesday, May 31st. Finally, Bank of America Corporation reissued a “buy” rating on shares of Exact Sciences Corporation in a report on Wednesday, July 26th. Six investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $40.51.
About Exact Sciences Corporation
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with our FREE daily email newsletter.